Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
The Company gained 4.1% and finished at $22.35. The daily volume was measured at 3.03 million shares. The 52-week high of the share price is $65.34 and the 52-week low is $19.59. The company has a market cap of $2.7 billion. Its latest closing price has a distance of -16.6% from SMA20 and is -35.38 down than SMA50. The stock currently has Price to Sales (P/S) value of 10.45 where Price to Book (P/B) value stands at 17.06.IONS is currently showing ROA (Return on Assets) value of -14.2% where ROE (Return on Equity) is -59.5%.
Return on equity (ROE) measures the rate of return on the ownership interest (shareholders’ equity) of the common stock owners. It measures a firm’s efficiency at generating profits from every unit of shareholders’ equity (also known as net assets or assets minus liabilities).
IONS is currently showing 120.6 million shares outstanding as compared with the 119.83 million total shares float.
The Stock has its Beta Value of 2.09 and ATR (Average True Range) of 1.99. The Weekly and Monthly Volatility of the stock are 5.58% and 7.42% respectively. The weekly performance of the company stands at 0.09 percent while it’s 1-month and 3-month returns are -28.87 percent and -38.78 percent.
By looking at Ionis Pharmaceuticals, Inc. (IONS) YTD (year to date) performance, the stock shows Negative value of -55.47%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is appreciating.
The High price target of the company’s Share is at $59 based on the calculations and analysis of 9 brokers. According to the analysts, the company has the Low Price target of $12 whereas, the Mean Target is estimated by the brokers is $33.
For an overview on Recommendation Trends, 1 Analysts assigned the stock as Strong Buy. 5 said it’s a Buy, 5 assigned Hold rating where 0 stated the stock as Underperform and 1 marked the stock as Sell.
While Looking at the Earnings Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as -$0.48 by 12 analysts. They are also projecting the Low EPS estimate as -$0.75 as compared to the Higher EPS estimate of -$0.19.
Now when we talk about Revenue Estimate for the current Fiscal Quarter, Average Revenue Estimate of Ionis Pharmaceuticals, Inc. (IONS) is projected as $44.18 Million where Low Revenue estimate and High Revenue Estimates are $25.2 Million and $79 Million respectively by 12 analysts.